Financial Health Assessment — Serrations Limited

Patient profile: A 25-year-old specialist manufacturer (tungsten carbide inserts for surgical instruments), privately held, small-company regime, unaudited abridged accounts under FRS 102 Section 1A. Four directors; controlled by Kaleidex Limited (>75%) alongside the Xxxxxxxname shown to subscribers family.

Two important caveats before we begin: 1. The latest accounts cover an 8-month period (1 May – 31 Dec 2025) because the company changed its year-end from 30 April to 31 December. Longer-period comparisons are therefore imperfect. 2. These are abridged accounts — no turnover, no profit-and-loss detail. Profitability can only be inferred from movements in the balance sheet, which conflate genuine trading results with any dividends paid. Treat profitability conclusions as directional, not precise.

1. Financial Health Score: B‑

A solid constitution with a chronic, slow-burning condition.

Overall: B‑. This is not a distressed business — it is a financially robust but quietly weakening one. The balance sheet is its strong heart; the erosion of reserves is the symptom that needs attention.

2. Key Vital Signs

The five-year trajectory of net assets (the "weight chart"):

2021 £895,125 ← peak 2022 £770,958 2023 £770,122 2024 £724,836 Apr25 £663,179 Dec25 £592,933 ← today

A steady, unbroken decline for four-and-a-half years. This is the single most important pattern in the data.

3. Diagnosis

What's healthy

• A strong, cash-rich, low-leverage balance sheet. Equity funds 72.5% of assets, long-term debt is trivial (£16,925), and liquidity is excellent on every measure. In the event of a trading shock, this business has real staying power.
• Filing health is good. Accounts and confirmation statement are both up to date, with comfortable headroom to the next deadlines. No red flags on the register, no insolvency events, a clean 25-year history.
• Cash is genuinely strong — nearly quadrupling from £78,641 (2023) to £309,851 (Dec 2025).

What's ailing

• Chronic reserve erosion. Net assets have fallen ~34% from the 2021 peak. On the latest 8-month run-rate, the business is losing roughly £105k a year. Left unchecked, that would consume the current equity base in about five to six years.
• The "cash paradox." Cash is rising while reserves are falling. That is a classic warning sign: the cash is not being generated by profit. It is being produced by stretching creditors (amounts due within one year jumped 86%, from £101k to £188k), building stock (up 78%, from £122k to £217k) and reducing fixed assets. In medical terms, the company is "sweating" its balance sheet to look fitter than its trading suggests.
• The £300k fixed-asset mystery. Tangible assets fell from £377,068 to £77,231 in eight months. An eight-month depreciation charge at 20% straight line on ~£377k would be roughly £50k — nowhere near £300k. This points to a disposal, reclassification, or write-down that is not explained in the abridged accounts and should be clarified. It is the largest single movement in the numbers.
• Stock build risk. Stocks nearly doubled in eight months. In a niche, precision-manufacturing business, this could be sensible pre-positioning for orders — or a sign of slow-moving or obsolete inventory. Without turnover data, this is a question to ask, not a conclusion to draw.

The underlying condition

Serrations looks like a mature, well-financed niche manufacturer whose profitability has been slipping — possibly through pricing pressure, rising costs, reduced volumes, or dividends that have outrun earnings. The balance sheet is absorbing the strain, but the direction of travel is unmistakable.

4. Prognosis

• Next 12 months — Stable. The liquidity buffer is large enough to absorb further losses without any solvency risk. No imminent danger.
• 2–5 years — Watchful. If the current rate of reserve erosion continues, equity would fall below £300k within roughly five years. Because cash is still rising, the deterioration is silent — it will not show up as a cash crisis until late in the day. That is precisely why it needs to be addressed now, while the company is strong.
• Key trigger points to monitor: a further fall in net assets; a reversal in the cash trend; stock write-downs; creditor days lengthening; loss of a major medical-sector customer; or further board/secretary changes (the company secretary resigned in December 2025 and a new director was appointed — worth confirming this is routine succession rather than instability).

5. Recommendations

1. Get a proper diagnosis of profitability. The abridged accounts hide the very thing that matters most. Produce monthly management accounts with gross margin, overheads, and profit trend so the cause of the reserve decline is visible. You cannot treat what you cannot see.
2. Explain the £300k fixed-asset movement. Confirm whether this was a disposal (and if so, what it generated), a reclassification, or a write-down. This single item distorts the whole picture.
3. Review stock. £217k of stock in a specialist manufacturer deserves scrutiny for ageing, obsolescence, and whether it is matched by firm orders.
4. Check supplier relationships. A 86% rise in short-term creditors may simply be normal year-end timing — or it may signal stretched payment terms. Confirm there is no supplier strain.
5. Clarify the dividend policy. Falling reserves can reflect losses or dividends exceeding profits. If it is the latter, ensure distributions are sustainable and not quietly consuming the company's capital.
6. Deploy the idle cash productively. With £310k on deposit and almost no debt, consider whether that capital could fund growth, automation, or a buffer against the medical-device market's cyclicality — rather than sitting idle.
7. Set early-warning thresholds. Agree a simple dashboard: net assets, cash, stock days, debtor days, creditor days. Flag any quarter where net assets fall further.
8. Strengthen governance continuity. With a secretary resignation and a new director in the same month, document succession and key-person plans for a business this specialised.

Names of the people mentioned are shown to subscribers. See subscription